Placebo + iptacopan
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Placebo + iptacopan
Placebo + iptacopan is a phase 3 stage product being developed by Novartis for C3G. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04817618. Target conditions include C3G.
What happened to similar drugs?
0 of 2 similar drugs in C3G were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05755386 | Phase 3 | Recruiting |
| NCT04817618 | Phase 3 | Recruiting |
Competing Products
6 competing products in C3G
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan | Novartis | Pre-clinical | 30 |
| Avacopan + Avacopan Matching Placebo | Amgen | Phase 2 | 35 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 38 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 2 | 33 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 34 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 20 |